Introduction: Intolerance of Octreotide is about 10 % of cases
Aim(s): To evaluate the tolerability of Lanreotide LAR in the case of intolerance of Octreotide LAR
Materials and methods: 5 patients with metastatic well-differentiated (G1-G2) functioning EP-NETs (2 – pancreas, 1 – cecum, 2 – small intestine).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: prof Vera Gorbunova
To read results and conclusion, please login ...
Further abstracts you may be interested in